Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 12/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 11/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 11/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Decane SCHEMBL27730245 | 0.88 | ALDH1A1 (0.53) | ALDH1A1GNAO1GNAI3GNAI1TSHR | |
| Octane SCHEMBL27534687 | 0.88 | ALDH1A1 (0.53) | ALDH1A1GNAO1GNAI3GNAI1TSHR | |
| Piperidine SCHEMBL3261905 | 0.88 | ALDH1A1 (0.53) | ALDH1A1 | |
| Azepane SCHEMBL28558375 | 0.88 | ALDH1A1 (0.53) | ALDH1A1 | |
| Heptane SCHEMBL27858869 | 0.85 | ALDH1A1 (0.50) | ALDH1A1GNAO1GNAI3GNAI1TSHR | |
| Heptane SCHEMBL29012288 | 0.85 | TSHR (0.50) | ALDH1A1GNAO1GNAI3GNAI1TSHR | |
| Piperidine SCHEMBL11122954 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GNAO1GNAI3GNAI1TSHR | |
| Piperidine SCHEMBL27826772 | 0.85 | ALDH1A1 (0.56) | ALDH1A1GNAO1GNAI3GNAI1TSHR | |
| Pyrrolidine SCHEMBL28552039 | 0.85 | ALDH1A1 (0.47) | ALDH1A1 | |
| Piperidine SCHEMBL22363260 | 0.84 | ALDH1A1 (0.39) | ALDH1A1PLA2G1BPLA2G2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753710-B1 | PROCESS FOR FORMING BRANCHED COMPOSITION CATALYTICALLY BY CARBON-HYDROGEN BOND ACTIVATION IN A SATURATED MOIETY | AKZO NOBEL NV (NL) | 2010-12-22 | — | — | EP | disclosed |
| US-7227040-B2 | Process for forming branched composition catalytically by carbon-hydrogen bond activation in a saturated moiety | AKZO NOBEL N.V. (NL) | 2007-06-05 | — | — | US | disclosed |
| EP-1753710-A1 | PROCESS FOR FORMING BRANCHED COMPOSITION CATALYTICALLY BY CARBON-HYDROGEN BOND ACTIVATION IN A SATURATED MOIETY | Akzo Nobel N.V. (NL) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005121063-A1 | PROCESS FOR FORMING BRANCHED COMPOSITION CATALYTICALLY BY CARBON-HYDROGEN BOND ACTIVATION IN A SATURATED MOIETY | AKZO NOBEL N.V. (NL) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272941-A1 | Process for forming branched composition catalytically by carbon-hydrogen bond activation in a saturated moiety | AKZO NOBEL N.V. (NL) | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272941-A1 | Process for forming branched composition catalytically by carbon-hydrogen bond activation in a saturated moiety | SCO2, HAO2, SOD1 | ALDH1A1 2459/4885GNAO1 2246/4885GNAI3 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.